||Last Updated: Nov 17th, 2006 - 22:35:04
Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis
While there have been significant advances in the use of gene expression profiling to assess a cancer prognosis, a Mayo Clinic review and analysis of existing lung cancer studies shows that this technology has not yet surpassed the accuracy of conventional methods used to assess survival in lung cancer patients.
Nov 17, 2006, 13:31
I-ELCAP study: Lung cancer can be detected early with annual low-dose CT screening
Lung cancer can be detected at its very earliest stage in 85 percent of patients using annual low-dose CT screening, and when followed by prompt surgical removal, the 10-year survival rate is 92 percent. These results, to be reported in the October 26 New England Journal of Medicine, would dramatically decrease the number of deaths from lung cancer — the number one cause of cancer deaths among both men and women in the U.S.
Oct 26, 2006, 19:24
Key to lung cancer chemotherapy resistance revealed
Scientists at Johns Hopkins have discovered how taking the brakes off a "detox" gene causes chemotherapy resistance in a common form of lung cancer. Products made by a gene called NRF2 normally protect cells from environmental pollutants like cigarette smoke and diesel exhaust by absorbing the materials and pumping them out of the cell. Another gene called KEAP1 encodes products that stop this cleansing process. But lung cancer cells sabotage the expression of these same genes to block assault from chemotherapy drugs.
Oct 11, 2006, 05:36
3D-CRT brings hope for inoperable lung cancers
Modern three-dimensional radiation therapy has been proven to be more successful at curing lung cancer than older two-dimensional radiation therapy for some patients with early stage lung cancer, according to a new study in the September 1, 2006 edition of the International Journal of Radiation Oncology * Biology * Physics, the official journal of the American Society for Therapeutic Radiology and Oncology (ASTRO).
Sep 1, 2006, 17:34
Sunitinib Malate shows promise against advanced form of lung cancer
Results of a multi-center clinical study of a drug currently approved for treatment of kidney cancer indicate that it may also be effective for people with recurrent and advanced lung cancer.
Jun 5, 2006, 16:31
Tarceva-Celebrex Combination therapy shows promising results in advanced lung cancer
An early phase study pairing an experimental targeted therapy with a common anti-inflammatory produced promising results in patients with advanced lung cancer, researchers at UCLA's Jonsson Cancer Center reported. Pairing the targeted therapy Tarceva with the anti-inflammatory drug Celebrex increased response rates in lung cancer patients by about three-fold, said Dr. Karen Reckamp, an assistant professor of hematology/oncology and lead author of the study. The research appears in the June 1 issue of Clinical Cancer Research, the peer-reviewed journal of the American Association of Cancer Research.
Jun 1, 2006, 13:41
Lung cancer susceptibility runs in families - Study
Studying thousands of people, researchers at The University of Texas M. D. Anderson Cancer Center have documented a 25 percent increased risk of developing one of a number of cancers in first-degree relatives of lung cancer patients who have never smoked compared to families of people who neither smoke nor have lung cancer.
Apr 3, 2006, 06:59
Do Variants in the GST Detoxification Genes Affect the Risk of Lung Cancer?
By the year 2020, global deaths from noncommunicable diseases are expected to increase by 77%. The projected rise is mainly due to the aging of the population and to an increase in the numbers of people exposed to tobacco. While antismoking campaigns have met with some success in developed countries, the tobacco epidemic is growing in many of the world's developing and most populous countries. Tobacco (a major risk factor not only for lung cancer but also for chronic obstructive pulmonary diseases such as emphysema) is expected to kill more people than any single disease, surpassing even the HIV epidemic.
Mar 8, 2006, 05:11
Tumor diameter - an important prognostic indicator for curability
Smaller tumors in the lungs appear to be less likely to have spread than larger tumors among patients with asymptomatic lung cancer, suggesting that early screening may be useful in detecting cancers that are still curable, according to a new article in the February 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Feb 15, 2006, 14:55
Palliative radiation can cure some NSCLC
About one in a hundred patients with apparently incurable non-small cell lung cancer (NSCLC) survive five or more years after being given relatively small doses of radiation therapy (RT) meant to ease symptoms, according to a new study. Published in the March 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study says a new subset of patients with NSCLC appears to have disease that is curable with minimal therapy, and may explain occasional cures attributed to unconventional therapies or faith healing.
Jan 23, 2006, 16:08
Bexarotene shows promise in lung cancer treatment
The ideal substance to prevent cancer would block tumor growth without causing unpleasant or dangerous side effects. Researchers at Washington University School of Medicine in St. Louis now report that a compound related to vitamin A shows promise in preventing or slowing tumor growth in mice prone to lung cancer.
Jan 18, 2006, 17:52
Aromatase inhibitors may slow growth of lung cancer as well
A medical student conducting research on a Howard Hughes Medical Institute (HHMI) fellowship and colleagues have managed to stop the growth of human lung cancer cells in mice with a class of breast cancer drugs called aromatase inhibitors. The studies are reported in the December 15, 2005 issue of the journal Cancer Research. “It was a natural progression of the work that had already been done linking estrogen and lung cancer,” said Olga Weinberg, who delayed her fourth year at Vanderbilt University School of Medicine to work on the project. The findings suggest a new way to treat lung cancer in women - a group whose death rate from the disease is surging.
Dec 15, 2005, 15:48
Women with Lung Cancer Live Longer than Men
Women with lung cancer are living longer than men, even when the disease is untreated. A new study presented at CHEST 2005, the 71st annual international scientific assembly of the of Chest Physicians (ACCP), found that in patients receiving treatment for lung cancer, women had significantly better survival rates than men. However, in untreated patients, women also had a 21 percent decreased risk of death as compared with men, leading researchers to believe lung cancer in women has a different biologic behavior and natural history than in men.
Nov 4, 2005, 22:01
Epidermal Growth Factor Receptor (EGFR) Mutations and Lung Cancer
Tyrosine kinases of the epidermal growth factor receptor (EGFR) family are frequently mutated in human cancers. Mutations in the tyrosine kinase domain of EGFR (encoded by exons 18â€“24) have mostly been found in lung cancers. Some, but not all, lung cancers carrying such mutations are responsive to treatment with small-molecule EGFR inhibitors, including the two FDA-approved drugs erlotinib and gefitinib.
Oct 7, 2005, 18:56
Number of Cigarettes Determine Extent of Lung Cancer Risk
Heavy smokers (more than 15 cigarettes per day) can reduce their risk of lung cancer if they decrease smoking by 50 percent, according to a study in the September 28 issue of JAMA. Lung cancer remains the leading cause of cancer death worldwide, and an estimated 90 percent of lung cancer cases are tobacco-related, according to background information in the article. Despite efforts to prevent people from beginning smoking and to encourage smoking cessation, the overall prevalence of cigarette smoking is still high and many smokers are unable or unwilling to completely quit.
Sep 28, 2005, 13:43
Dietary Phytoestrogens Reduce Risk of Lung Cancer
A diet higher in plant-derived compounds known as phytoestrogens is linked with a lower lung cancer risk, according to a study in the September 28 issue of JAMA. Phytoestrogens are plant-derived nonsteroidal compounds found in soy products, grains, carrots, spinach, broccoli, and other fruits and vegetables, according to background information in the article. Phytoestrogens have been shown to have a protective effect against some solid tumors, but there has been little epidemiologic research focused on dietary intake of phytoestrogens and lung cancer risk.
Sep 28, 2005, 13:32
PGT202 trial demonstrated survival advantage with paclitaxel poliglumex
At a presentation at the UBS Global Life Sciences Conference, Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) presented new results from a recently completed phase II clinical trial of XYOTAX in the first-line treatment of men and women with advanced non-small cell lung cancer (NSCLC).
Sep 28, 2005, 13:01
Epigenetic Activity Silences Rb2/P130 Gene In Lung Cancer
The attaching of methyl--or chemical--groups onto DNA sequences within the tumor suppressing gene Rb2/p130 can cause the gene to cease functioning in non-small lung cancer cells (NSLC) and retinoblastoma cells, researchers at Temple University's Sbarro Institute for Cancer Research and Molecular Medicine and Italy's University of Siena have discovered.
Sep 14, 2005, 02:20
Better Combination Therapy for Patients with Locally Advanced Lung Cancer
While researchers have learned in the last decade that combining chemotherapy with radiation is better than radiation alone for treating non-small cell lung cancer patients with locally advanced disease – cancer confined to the lungs – finding the right combination of drugs – and the best timing of treatment – has been tricky.
Sep 4, 2005, 08:00
Diagnostic Strategy May Help Determine Stage Of Lung Cancer More Accurately
A preoperative testing strategy combining two procedures may help improve the accuracy of determining the stage of lung cancer, according to an article in the August 24/31 issue of JAMA.
Aug 24, 2005, 19:30
Nimotuzumab Approved for Non-Small-Cell Lung Cancer Trial
YM BioSciences Inc. , the cancer product development company, today announced that Health Canada has cleared a Clinical Trial Application (CTA) for a multi-center Phase I/II trial utilizing YM's anti-EGFr monoclonal antibody, nimotuzumab (TheraCIM).
Aug 18, 2005, 11:56
Common lung cancer may begin in newly discovered stem cells
The most common form of lung cancer may begin in a group of newly isolated lung stem cells, according to researchers from the Howard Hughes Medical Institute.
Jun 17, 2005, 03:42
First Phase III Study to Extend Median Survival Beyond One Year in Advanced Lung Cancer
Genentech, Inc. (NYSE: DNA) and Roche (SWX Zurich) today announced that data from a Phase III study (E4599) of Avastin™ (bevacizumab) plus paclitaxel and carboplatin chemotherapies in first-line non-squamous, non-small cell lung cancer (NSCLC) showed the study met its primary efficacy endpoint of improving overall survival.
May 14, 2005, 07:18
Survival Not Improved With Dose-Dense Chemotherapy for Small-Cell Lung Cancer
A randomized trial has found that a dose-dense regimen of chemotherapy with blood progenitor cell support did not improve survival compared with standard-dose chemotherapy in patients with small-cell lung cancer (SCLC). However, patients who received the dose-dense regimen had fewer infections and fewer days of treatment than patients who received standard chemotherapy.
May 4, 2005, 17:26
Age not a Limiting Factor in Lung Cancer Therapy
Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients, according to a new study appearing in the June 1, 2005 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society
Apr 26, 2005, 02:02
Early detection of Lung Cancer
This study was aimed at the detection of lung cancer in its early stages amongst high-risk persons by means of Computerised Axial Tomography (CAT).
Apr 20, 2005, 20:19
Clinical Trial of Gefitinib for Advanced Lung Cancer Closes Early
Researchers have closed a randomized clinical trial comparing gefitinib (Iressa™) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.
Apr 20, 2005, 19:23
Abnormal lung cancer screening results may help smokers quit
According to a new study, smokers who receive multiple abnormal results using computed tomography (CT) to screen for lung cancer are more likely to quit, suggesting an opportunity for doctors to motivate smokers to quit smoking.
Apr 11, 2005, 12:41
Aerosolized Cyclosporine Shows Significant Results in Chronic Rejection of Allogenic Lung Transplants
The Pulmonary-Allergy Drugs Advisory Committee will review Chiron’s aerosolized cyclosporine Pulminiq for lung transplantation June 6.
Chiron is seeking approval for use of aerosolized cyclosporine in combination with standard immunosuppressive therapy to increase survival and prevent chronic rejection in patients receiving allogenic lung transplants.
Mar 24, 2005, 09:22
Bevacizumab plus Chemotherapy can Prolong Lung Cancer Survival
Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.
Mar 18, 2005, 23:41